The benefits – and challenges – of in-house CAR T-cell therapy

The Sheba Medical Center in Israel has an advanced hemato-oncology center that offers in-house CAR T-cell therapy, the revolutionary immunotherapy that alters a patient’s white blood cells to kill cancer cells. 

By keeping the entire process at the hospital, and not sending the cells to an external lab, the quality of the T-cells are better preserved and the whole process can be completed in 10 days. Sheba has successfully treated hundreds of patients with CAR-T cell therapy.

Prof. Arnon Nagler

Arnon Nagler is director of the Division of Hematology and the Bone Marrow Transplantation and Cord Blood Bank at the Chaim Sheba Medical Center, Tel-Hashomer, Israel and Professor of Medicine at The Tel Aviv University, Tel-Aviv, Israel. 

He has been working in the field of bone marrow transplantation for hematological malignancies for the last 25 years and is one of the pioneers of the non-myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders. His main contributions and scientific interests are hematopoietic stem cell transplantation,

The post The benefits – and challenges – of in-house CAR T-cell therapy appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

cell therapy
immunotherapy
medical